Dr. Xinjun Liang 梁新军
Chief Physician
Department of Medical Oncology, Hubei Cancer Hospital, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionDr. Liang holds a medical doctorate and completed postdoctoral research at Roswell Park Cancer Institute in the United States. A chief physician and master’s supervisor, Dr. Liang was selected for the Wuhan Young and Middle-Aged Medical Backbone Talent Program and the Research-Oriented Clinical Physician Funding Program of Tongji Medical College, Huazhong University of Science and Technology.
Professional roles
- Council Member, Youth Council of China Anti-Cancer Association
- Council Member and Head of Academic Department, Hubei Anti-Cancer Association
- Youth Committee Member, Colorectal Cancer Professional Committee of China Anti-Cancer Association
- Committee Member, Tumor Metastasis Professional Committee of China Anti-Cancer Association
Name order: in Chinese the family name comes first (Liang Xinjun). Papers usually list the name as Xinjun Liang or Liang X.
Selected publications
63 papers on PubMed matched by name and affiliation; 15 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): Molecular studies on the impact of microbiome on anticancer drug resistance. PubMed 42375360
- J Clin Oncol, 2026 (first author): From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer. PubMed 41557970
- Cancers (Basel), 2026 (senior author): Lynch Syndrome as a Spectrum of Four Distinct Genetic Disorders: Toward Genotype-Guided Precision Management in the NGS Era. PubMed 41681978
- J Immunol Res, 2026 (senior author): Immunotherapy Resistance in dMMR/MSI-H Colorectal Cancer: Unraveling Mechanisms and Exploring Overcoming Strategies. PubMed 42590903
- Front Oncol, 2024 (senior author): Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma. PubMed 39502318
- ACS Appl Mater Interfaces, 2023 (senior author): Manganese Dioxide/Gold-based Active Tumor Targeting Nanoprobes for Enhancing Photodynamic and Low-Temperature-Photothermal Combination Therapy in Lung Cancer. PubMed 37974457
- Int Immunopharmacol, 2022 (senior author): Notoginsenoside R1 induces oxidative stress and modulates LPS induced immune microenvironment of nasopharyngeal carcinoma. PubMed 36279666
- Eur J Immunol, 2022 (senior author): Peripheral Polyfunctional PD1(+) CD8(+) T cells demonstrated strong immune protection in non-small cell lung cancer. PubMed 35689391
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion